{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:42:55Z","timestamp":1760013775557},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.ijantimicag.2007.05.023","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T11:16:05Z","timestamp":1187867765000},"page":"422-427","source":"Crossref","is-referenced-by-count":24,"title":["Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"30","author":[{"suffix":"Jr.","given":"John E.","family":"Conte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"McIver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Zurlinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2007.05.023_bib1","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1128\/AAC.47.6.1790-1797.2003","article-title":"Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000\u20132001 and 2001\u20132002 TRUST studies in the United States","volume":"47","author":"Karlowsky","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.47.1.292-296.2003","article-title":"Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team","volume":"47","author":"Jones","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1469-0691.2002.00392.x","article-title":"In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe","volume":"8","author":"Critchley","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.43.2.421","article-title":"Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin\u2013dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains","volume":"43","author":"Jones","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1179\/joc.1996.8.6.411","article-title":"In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains","volume":"8","author":"Flynn","year":"1996","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.CCM.0000150265.42067.4C","article-title":"Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079904X2556","article-title":"Clinical implications of 750mg, 5-day levofloxacin for the treatment of community-acquired pneumonia","volume":"20","author":"File","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10096-003-1060-x","article-title":"Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia","volume":"23","author":"Erard","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib11","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1086\/383320","article-title":"Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia","volume":"189","author":"Drusano","year":"2004","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2007.05.023_bib12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1098-3597(03)90026-3","article-title":"A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia","author":"File","year":"2003","journal-title":"Clin Cornerstone"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.49.4.1633-1635.2005","article-title":"Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens","volume":"49","author":"Hermsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib16","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1128\/AAC.42.4.885","article-title":"Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers","volume":"42","author":"Chien","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib17","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/AAC.43.9.2323","article-title":"Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients","volume":"43","author":"Piscitelli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2006.03.022","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects","volume":"28","author":"Conte","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1378\/chest.125.3.965","article-title":"Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults","volume":"125","author":"Capitano","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.119.4.1114","article-title":"Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects","volume":"119","author":"Gotfried","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib21","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","article-title":"Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults","volume":"47","author":"Rodvold","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.46.2.586-589.2002","article-title":"Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"46","author":"Drusano","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1 Suppl","key":"10.1016\/j.ijantimicag.2007.05.023_bib23","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1378\/chest.129.1_suppl.104S","article-title":"Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Braman","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2005.08.015","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem","volume":"26","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1183\/09031936.93.03080886","article-title":"Azithromycin concentrations at the sites of pulmonary infection","volume":"3","author":"Baldwin","year":"1990","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1164\/ajrccm\/138.1.74","article-title":"Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method","volume":"138","author":"Willcox","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0732-8893(03)00165-2","article-title":"Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000\u20132002)","volume":"47","author":"Sader","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/AAC.47.4.1447-1448.2003","article-title":"In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae","volume":"47","author":"Roblin","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/dkg365","article-title":"Bactericidal activity of levofloxacin against Mycoplasma pneumoniae","volume":"52","author":"Duffy","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0924-8579(02)00031-6","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs","volume":"19","author":"Mouton","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/AAC.27.1.42","article-title":"Antibiotic uptake by alveolar macrophages of smokers","volume":"27","author":"Hand","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00003088-200443060-00003","article-title":"Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin","volume":"43","author":"Conte","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib35","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1128\/AAC.45.10.2891-2896.2001","article-title":"Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations","volume":"45","author":"Conte","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib36","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.47.9.2749-2755.2003","article-title":"Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration\/MIC versus area under the curve\/MIC ratios","volume":"47","author":"Scaglione","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.43.3.672","article-title":"Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection","volume":"43","author":"Lacy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2007.05.023_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000048487","article-title":"Pharmacodynamics and pharmacokinetics of levofloxacin","volume":"46","author":"Nightingale","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0149-2918(04)80001-8","article-title":"Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem","volume":"26","author":"Mattoes","year":"2004","journal-title":"Clin Ther"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2007.05.023_bib40","first-page":"38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","author":"Drusano","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib41","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00003088-200039030-00002","article-title":"Comparative pharmacokinetics of the carbapenems: clinical implications","volume":"39","author":"Mouton","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib44","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1592\/phco.22.15.1216.33484","article-title":"Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit","volume":"22","author":"Rebuck","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/dki059","article-title":"Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages","volume":"55","author":"Seral","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib46","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.37.9.1831","article-title":"Quinolones in treatment of human brucellosis: comparative trial of ofloxacin\u2013rifampin versus doxycycline\u2013rifampin","volume":"37","author":"Akova","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib47","first-page":"921","article-title":"Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis","volume":"23","author":"Saltoglu","year":"2002","journal-title":"Saudi Med J"},{"key":"10.1016\/j.ijantimicag.2007.05.023_bib48","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1128\/AAC.48.12.4562-4565.2004","article-title":"Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii","volume":"48","author":"Alcaide","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907002920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907002920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T22:04:34Z","timestamp":1684015474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857907002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0924857907002920"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.05.023","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}